Investor Presentation for Quarter- IV and Financial year ended on March 31, 2026.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma reported FY26 standalone revenue of Rs 811 Cr, down 12% from Rs 922 Cr in FY25, with EBITDA declining 36% to Rs 101 Cr and PAT falling 58% to Rs 45 Cr. Q4 FY26 showed sequential improvement with PAT of Rs 30 Cr versus Rs 28 Cr in Q4 FY25. The company highlighted its positioning as India's only USFDA-approved sterile cephalosporin manufacturer and announced capital allocation plans including Rs 750 Cr for a 1,000 MT 7ACA facility (commissioning FY27) and Rs 200 Cr for Cefiderocol access project. Management targets 5-6 sterile US product launches by 2030, leveraging the pending Dhanuka merger to create an integrated platform from KSM to finished dosage. The company noted the global cephalosporin API market at $3 billion with 15-20% annual growth potential.
The FY26 results show operational challenges with declining margins (EBITDA margin fell from 17% to 12%), but management's multi-year investment roadmap signals a transition from turnaround to platform creation. The 7ACA integration and FDF expansion strategy could improve margin quality over FY27-30, though near-term pressure remains as these projects ramp up.